Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  AMAG Pharmaceuticals, Inc.    AMAG

AMAG PHARMACEUTICALS, INC. (AMAG)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

AMAG Pharmaceuticals : Appoints Tracy Palmer Berns as Chief Compliance Officer

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/04/2017 | 10:25am CEST

Release date- 02102017 - WALTHAM - AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the appointment of Tracy Palmer Berns as chief compliance officer effective immediately.

She will report to Joseph Vittiglio, general counsel and senior vice president of legal affairs and quality.

In her role at AMAG, Ms. Berns will be responsible for the company's compliance program and therapeutic-product legal team and provide legal advice on regulatory, development, pharmacovigilance and quality matters. Additionally, she will further strengthen the organization's culture to continue to prioritize ethics and compliance.

Ms. Berns brings more than 20 years of healthcare industry experience, creating effective compliance programs focused on policies, training, risk assessment, monitoring, investigations and discipline. Most recently, she served as the vice president of ethics and compliance within the Minimally Invasive Therapies Group at Medtronic, reporting to the president of the division and Medtronic's chief ethics and compliance officer.

Prior to this position, she was vice president and chief compliance and regulatory counsel at Covidien, where she was responsible for the company's global compliance program to ensure compliance with relevant laws and regulations.

'I am confident that Tracy's broad experience leading compliance programs in other healthcare organizations will be beneficial to AMAG today, and in the future as we continue to expand our product portfolio,' said Mr. Vittiglio. 'Her insights and expertise will be helpful as we continue to develop and market novel therapeutics to address significant unmet medical needs.'

Ms. Berns received her law degree from Columbia University and her Bachelor's degree at Knox College in Illinois.

Inducement Equity Awards

In connection with Ms. Berns entering into employment with AMAG, the Board of Directors of AMAG approved awards to Ms. Berns of (i) an option to purchase 20,000 shares of common stock and (ii) 9,000 restricted stock units. The option will have an exercise price equal to the closing price of AMAG's common stock on the grant date and will be exercisable in four equal annual installments beginning on the first anniversary of the grant date. The option will have a ten-year term and be subject to the terms and conditions of the stock option agreement pursuant to which the option will be granted. The restricted stock units will vest in three equal annual installments beginning on the first anniversary of the grant date and will be subject to the restricted stock unit agreement pursuant to which the restricted stock units will be granted. These equity awards will be granted without stockholder approval as inducements material to Ms. Berns entering into employment with AMAG in accordance with NASDAQ Listing Rule 5635(4).

About AMAG

AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of maternal and women's health, anemia management and cancer supportive care. Through CBR, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including but not limited to statements regarding Ms. Berns' responsibilities at AMAG related to the company's compliance program and its' therapeutic-product legal team, including providing legal advice on regulatory, development, pharmacovigilance and quality matters and strengthening the organization's culture to continue to prioritize ethics and compliance; AMAG's belief that Ms. Berns' broad experience leading compliance programs in other healthcare organizations will be beneficial to AMAG as it continues to expand its product portfolio and that her insights and expertise will be helpful as the company continues to develop and market novel therapeutics to address significant unmet medical needs and beliefs that newborn stem cells have the potential to play a valuable role in the development of regenerative medicine are forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements.

Such risks and uncertainties include, among others, those identified in AMAG's Securities and Exchange Commission (SEC) filings, including AMAG's Annual Report on Form 10-K for the year ended December 31, 2016 and subsequent filings with the SEC. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made.

AMAG disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

AMAG Pharmaceuticals and Feraheme are registered trademarks of AMAG Pharmaceuticals, Inc. CBR is a registered trademark of Cbr Systems, Inc.

Contact:

Tel: 617-498-3332

(c) 2017 Electronic News Publishing -, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
AMAG PHARMACEUTICALS, INC. -1.20% 20.65 Delayed Quote.55.85%
MEDTRONIC PLC 0.38% 97.85 Delayed Quote.20.72%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AMAG PHARMACEUTICALS, INC.
09/20AMAG PHARMACEUTICALS : Summary ToggleAMAG Pharmaceuticals Partners With Emmy-Nom..
PU
09/20AMAG Pharmaceuticals Partners With Emmy-Nominated Actress Cheryl Hines and Dr..
GL
09/18Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2018 Result..
AQ
09/10AMAG PHARMACEUTICALS : Pays Off $475 Million of Senior Secured Notes
AQ
09/07AMAG PHARMACEUTICALS : Pays Off $475 Million of Senior Secured Notes
AQ
09/06AMAG Pharmaceuticals Pays Off $475 Million of Senior Secured Notes
GL
08/23AMAG Pharmaceuticals to Present at Upcoming Investor Conferences
GL
08/10AMAG PHARMACEUTICALS : Completes Divestiture of Cord Blood Registry
AQ
08/10AMAG PHARMACEUTICALS : Appoints Brian Robinson, M.D. as Senior Vice President of..
AQ
08/10Antares Pharma Reports Second Quarter 2018 Operating and Financial Results
AQ
More news
News from SeekingAlpha
09/19The Magic Formula Needs An Upgrade 
08/31Amneal inks deal with American Regent on Makena and progress on its business .. 
08/27AMAG PHARMACEUTICALS : A Well-Positioned Player In The Pharmaceutical Space 
08/20ANTARES PHARMA : Proven Business Model Set To Move Much Higher 
08/04AMAG Pharmaceuticals, Inc. (AMAG) CEO Bill Heiden on Q2 2018 Results - Earnin.. 
Financials ($)
Sales 2018 531 M
EBIT 2018 -82,9 M
Net income 2018 -131 M
Debt 2018 450 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 2,19x
EV / Sales 2019 2,98x
Capitalization 712 M
Chart AMAG PHARMACEUTICALS, INC.
Duration : Period :
AMAG Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMAG PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 9
Average target price 23,3 $
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
William K. Heiden President, Chief Executive Officer & Director
Gino Santini Chairman
Edward H. Myles CFO, Treasurer, Principal Accounting Officer & SVP
Julie Krop Chief Medical Officer & Executive Vice President
Brian Robinson Senior Vice President-Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
AMAG PHARMACEUTICALS, INC.55.85%712
JOHNSON & JOHNSON1.62%383 312
PFIZER21.65%258 285
NOVARTIS-0.63%216 108
ROCHE HOLDING LTD.-4.60%211 501
MERCK AND COMPANY25.79%189 092